Cerylid regroups, lays off staff
Thursday, 04 September, 2003
Unlisted Melbourne company Cerylid Biosciences has reorganised, necessitating the layoff of a portion of its staff.
But management at the natural products drug discovery company was quick to reassure Australian Biotechnology News that the strategy is not a sign of trouble for the company, but rather a step taken to realign the needs of the business.
"The reorganisation is due to a realignment of projects, and the company's needs going forward," said Cerylid CEO Dr Jackie Fairley.
"Like many in the sector, we're keeping an eye on cash burn, but we're in a strong cash position, with two years of cash available."
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
